Bioreactor Group, Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany.
Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California.
Cell Prolif. 2019 Jul;52(4):e12604. doi: 10.1111/cpr.12604. Epub 2019 May 8.
For optimized expansion of human-induced pluripotent stem cells (hiPSCs) with regards to clinical applications, we investigated the influence of the inoculum density on the expansion procedure in 3D hollow-fibre bioreactors.
Analytical-scale bioreactors with a cell compartment volume of 3 mL or a large-scale bioreactor with a cell compartment volume of 17 mL were used and inoculated with either 10 × 10 or 50 × 10 hiPSCs. Cells were cultured in bioreactors over 15 days; daily measurements of biochemical parameters were performed. At the end of the experiment, the CellTiter-Blue Assay was used for culture activity evaluation and cell quantification. Also, cell compartment sections were removed for gene expression and immunohistochemistry analysis.
The results revealed significantly higher values for cell metabolism, cell activity and cell yields when using the higher inoculation number, but also a more distinct differentiation. As large inoculation numbers require cost and time-extensive pre-expansion, low inoculation numbers may be used preferably for long-term expansion of hiPSCs. Expansion of hiPSCs in the large-scale bioreactor led to a successful production of 5.4 × 10 hiPSCs, thereby achieving sufficient cell amounts for clinical applications.
In conclusion, the results show a significant effect of the inoculum density on cell expansion, differentiation and production of hiPSCs, emphasizing the importance of the inoculum density for downstream applications of hiPSCs. Furthermore, the bioreactor technology was successfully applied for controlled and scalable production of hiPSCs for clinical use.
为了优化人类诱导多能干细胞(hiPSCs)的临床应用扩展,我们研究了接种密度对 3D 中空纤维生物反应器中扩增过程的影响。
使用细胞腔体积为 3 mL 的分析规模生物反应器或细胞腔体积为 17 mL 的大规模生物反应器,分别以 10×10 或 50×10 的 hiPSCs 进行接种。细胞在生物反应器中培养 15 天;每天测量生化参数。实验结束时,使用 CellTiter-Blue 测定法评估培养物活性和细胞定量。此外,还取出细胞腔部分进行基因表达和免疫组织化学分析。
结果表明,使用较高的接种数量时,细胞代谢、细胞活性和细胞产量的值显著更高,但分化也更为明显。由于较大的接种数量需要成本和时间密集的预扩增,因此可能更倾向于使用较低的接种数量进行 hiPSCs 的长期扩增。在大规模生物反应器中扩增 hiPSCs 可成功生产 5.4×10 的 hiPSCs,从而获得足够的细胞量用于临床应用。
总之,结果表明接种密度对 hiPSCs 的扩增、分化和生产有显著影响,强调了接种密度对 hiPSCs 下游应用的重要性。此外,生物反应器技术成功应用于 hiPSCs 的可控和规模化生产,以满足临床应用的需求。